CD19 × BCMA RetroT-enabled in vivo CAR program / CREATE Medicines - LARVOL DELTA

CREATE Medicines Expands Clinical In Vivo CAR Pipeline and LNP Technology Suite by Forming Strategic Collaboration With WestGene (PRNewswire) - "The collaboration expands CREATE's access to cutting edge targeted LNP technologies, combining CREATE's leading in vivo CAR platform with WestGene's proprietary tLNP delivery platform....CRT-403, a dual-target CD19 × BCMA in vivo CAR-T therapy for autoimmune disease that targets both B cells and antibody-producing plasma cells; CRT-401, a dual-component HER2 × TROP2 multi-immune in vivo CAR program for solid tumors; A CD19 × BCMA RetroT-enabled in vivo CAR program...."

Licensing / partnership • Immunology • Oncology • Solid Tumor